Inhaled Biologics: Preparing for a Future Beyond Small Molecules
The IPAC-RS workshop brings together industry and regulatory leaders to explore pulmonary and nasal delivery of biologics. Discussion topics will include practical and regulatory considerations regarding analytical method establishment, formulation design and development, device selection, manufacturing, stability, characterization, and control of inhaled and nasal large molecule formulations.
Date: September 4-5, 2024
Location: Washington, D.C.
JOIN US!
Join Catalent at the IPAC-RS workshop in Washington, DC to tackle gaps in the current regulatory science of inhaled and nasal biologics and help shape the future of biologics delivery. Complete the form to schedule a meeting with Catalent at the Inhaled Biologics: Preparing for a Future Beyond Small Molecules Workshop!
FEATURED SPEAKING SESSION
Title: Testing Requirements for Protein Biologics Therapies
Date: Wednesday, September 4, 2024
Time: 10:45 – 11:30 AM EDT
MODERATOR
Alan Watts, Ph.D.
Director Innovation and Partnerships
Orally Inhaled Delivery
Catalent
Co-Chair, Workshop Organizing Committee
SPEAKER
Wai Lam Ling, Ph.D.
Vice President
Scientific Advisory
Catalent
ABOUT CATALENT
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.
